Medical debt is associated with population health and increased mortality

SAN DIEGO — Af­ter Graphite Bio’s im­plo­sion, Matthew Por­teus wants to do things dif­fer­ent­ly. The Stan­ford re­searcher’s stint at the biotech end­ed with Graphite sell­ing

Bio­nom­ics tout­ed the reg­is­tra­tional po­ten­tial of its post-trau­mat­ic stress dis­or­der drug af­ter it hit the pri­ma­ry end­point in a Phase IIb tri­al, trig­ger­ing the com­pa­ny’s